Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1966 1
1967 1
1969 1
1971 2
1972 2
1973 1
1975 4
1976 3
1977 5
1978 7
1979 11
1980 10
1981 8
1982 7
1983 15
1984 22
1985 16
1986 27
1987 17
1988 22
1989 39
1990 38
1991 23
1992 35
1993 37
1994 44
1995 35
1996 33
1997 40
1998 36
1999 46
2000 65
2001 63
2002 71
2003 82
2004 79
2005 88
2006 91
2007 111
2008 83
2009 108
2010 88
2011 109
2012 85
2013 108
2014 113
2015 137
2016 165
2017 165
2018 182
2019 177
2020 227
2021 257
2022 244
2023 286
2024 96

Text availability

Article attribute

Article type

Publication date

Search Results

3,499 results

Results by year

Filters applied: . Clear all
Page 1
Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
Ogo T, Shimokawahara H, Kinoshita H, Sakao S, Abe K, Matoba S, Motoki H, Takama N, Ako J, Ikeda Y, Joho S, Maki H, Saeki T, Sugano T, Tsujino I, Yoshioka K, Shiota N, Tanaka S, Yamamoto C, Tanabe N, Tatsumi K; Study Group. Ogo T, et al. Among authors: yamamoto c. Eur Respir J. 2022 Jul 7;60(1):2101694. doi: 10.1183/13993003.01694-2021. Print 2022 Jul. Eur Respir J. 2022. PMID: 34824052 Free PMC article. Clinical Trial.
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, Maruyama Y, Taoda Y, Kasamatsu K, Suto T, Kouki K, Nakahashi A, Kawashima S, Sanaki T, Toba S, Uemura K, Mizutare T, Ando S, Sasaki M, Orba Y, Sawa H, Sato A, Sato T, Kato T, Tachibana Y. Unoh Y, et al. Among authors: yamamoto s. J Med Chem. 2022 May 12;65(9):6499-6512. doi: 10.1021/acs.jmedchem.2c00117. Epub 2022 Mar 30. J Med Chem. 2022. PMID: 35352927 Free PMC article.
Ionic immune suppression within the tumour microenvironment limits T cell effector function.
Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP. Eil R, et al. Among authors: yamamoto tn. Nature. 2016 Sep 22;537(7621):539-543. doi: 10.1038/nature19364. Epub 2016 Sep 14. Nature. 2016. PMID: 27626381 Free PMC article.
Potassium-mediated suppression of Akt-mTOR signalling and T cell function is dependent upon the activity of the serine/threonine phosphatase PP2A. Although the suppressive effect mediated by elevated [K(+)](e) is independent of changes in plasma membrane potential (V(m)), …
Potassium-mediated suppression of Akt-mTOR signalling and T cell function is dependent upon the activity of the serine/threonine phosphatase …
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer.
Fujimoto D, Miura S, Tomii K, Sumikawa H, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Kijima T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Tokito T, Murakami S, Tamiya A, Yokouchi H, Watanabe S, Yamaguchi O, Morinaga R, Jodai T, Ito K, Shiraishi Y, Kogure Y, Shibaki R, Yamamoto N. Fujimoto D, et al. Among authors: yamamoto n. Sci Rep. 2023 Mar 6;13(1):3698. doi: 10.1038/s41598-023-30676-y. Sci Rep. 2023. PMID: 36878936 Free PMC article.
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
Ando K, Nakamura Y, Kitao H, Shimokawa M, Kotani D, Bando H, Nishina T, Yamada T, Yuki S, Narita Y, Hara H, Ohta T, Esaki T, Hamamoto Y, Kato K, Yamamoto Y, Minashi K, Ohtsubo K, Izawa N, Kawakami H, Kato T, Satoh T, Okano N, Tsuji A, Yamazaki K, Yoshino T, Maehara Y, Oki E. Ando K, et al. Among authors: yamamoto y. Br J Cancer. 2023 Oct;129(6):1032-1039. doi: 10.1038/s41416-023-02378-9. Epub 2023 Aug 2. Br J Cancer. 2023. PMID: 37532830
Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Kurozumi A, Hatazaki M, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Kato K, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Katakami N, et al. Among authors: yamamoto t. Cardiovasc Diabetol. 2023 Jun 22;22(1):143. doi: 10.1186/s12933-023-01879-4. Cardiovasc Diabetol. 2023. PMID: 37349722 Free PMC article. Clinical Trial.
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).
Niikura N, Yamanaka T, Nomura H, Shiraishi K, Kusama H, Yamamoto M, Matsuura K, Inoue K, Takahara S, Kita S, Yamaguchi M, Aruga T, Shibata N, Shimomura A, Ozaki Y, Sakai S, Kiga Y, Izutani T, Shiosakai K, Tsurutani J. Niikura N, et al. Among authors: yamamoto m. NPJ Breast Cancer. 2023 Oct 11;9(1):82. doi: 10.1038/s41523-023-00584-5. NPJ Breast Cancer. 2023. PMID: 37821514 Free PMC article.
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.
Takeda M, Shimokawa M, Nakamura A, Nosaki K, Watanabe Y, Kato T, Hayakawa D, Tanaka H, Takahashi T, Oki M, Tachihara M, Fujimoto D, Hayashi H, Yamaguchi K, Yamamoto S, Iwama E, Azuma K, Hasegawa K, Yamamoto N, Nakagawa K. Takeda M, et al. Among authors: yamamoto n, yamamoto s. Lung Cancer. 2023 Mar;177:44-50. doi: 10.1016/j.lungcan.2023.01.011. Epub 2023 Jan 28. Lung Cancer. 2023. PMID: 36731290 Free article. Clinical Trial.
The authors reply: Re: Yamamoto R, Sugiura T, Ashida R, Ohgi K, Yamada M, Otsuka S, and Uesaka K. Prognostic value of carbohydrate antigen 19-9 and the surgical margin in extrahepatic Cholangiocarcinoma. Ann Gastroenterol Surg. 2022;6:307-315.
Yamamoto R, Sugiura T, Ashida R, Ohgi K, Yamada M, Otsuka S, Uesaka K. Yamamoto R, et al. Ann Gastroenterol Surg. 2023 Feb 21;7(3):535-536. doi: 10.1002/ags3.12667. eCollection 2023 May. Ann Gastroenterol Surg. 2023. PMID: 37152786 Free PMC article.
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L).
Wakuda K, Kenmotsu H, Sato Y, Nakamura A, Akamatsu H, Tachihara M, Miura S, Yokoyama T, Mori K, Nakagawa K, Yamamoto N. Wakuda K, et al. Among authors: yamamoto n. BMC Cancer. 2023 Sep 25;23(1):902. doi: 10.1186/s12885-023-11417-w. BMC Cancer. 2023. PMID: 37749521 Free PMC article.
3,499 results